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ambulation since the patients have less postoperative
pain.
The article by Nakamura et al. asks what to
do when patients do not comply with the IPCD. My
suggestion would be to emphasize to the nurses and
the patient the importance of the devise and in addition
use a spinal anesthetic. Our patients remove the
devices the morning after surgery and begin
ambulation.
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To the Editor:
The editorial comments of our paper by
Dr.H.Samaratunga, Dr. Rodolfo Montironi, and Dr.
Liang Cheng were very informative on a lesion that
is one of the most frequent mimics of prostatic ad-
enocarcinoma. It occurs most frequently in the pos-
terior lobe or peripheral zone (1-3) and gained im-
portance with the increasing use of needle biopsies
for the detection of prostatic carcinoma (4). Moore
(1), in 1936, was one of the first authors to describe
prostatic atrophy in a systematic autopsy study. He
found that there was a strong correlation with age
and, according to his study, prostatic atrophy is initi-
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ated during the 5th decade and continues as a pro-
gressive process into the 8th decade. It is a frequent
lesion: 85% in autopsies and 83.7% in needle biop-
sies (5,6).
Why this lesion mimics adenocarcinoma?
Histologically prostatic atrophy may be partial or
complete. The latter is subtyped in simple, hyperplas-
tic (or post-atrophic hyperplasia), and sclerotic (5). It
seems that the subtypes represent a morphologic con-
tinuum of a single lesion (4). Partial atrophy and hy-
perplastic (or postatrophic hyperplasia) most fre-
quently mimic adenocarcinoma. Hyperplastic atrophy
shows small acini closely packed together and lined
by atrophic epithelium. Fibrosis is present or not in
the stroma. When present, the proliferation is irregu-
lar and can result in distortion of the acini simulating
stromal infiltration (Figure-1). Partial atrophy was de-
scribed by Oppenheimer et al. (7). The name is due
to the fact that there is partial preservation of the cy-
toplasm simulating neoplastic micro-acini (Figure-2).
An additional pitfall for the surgical pathologist is
the fact that in partial atrophy the basal cells may be
scattered and in some acini may be completely ab-
sent (Figure-3).
There are some findings associated to the etio-
pathogenesis of the lesion. Atrophy is clearly associ-
ated to advanced age (1,5). Radiotherapy and hor-
monal deprivation are associated with diffuse atro-
phy. Inactive or active inflammation is a frequent
cause for the lesion (8) and based on a study on au-
topsies there is evidence that chronic local ischemia
may also be a cause of atrophy (5).  However, many
examples of atrophy are still considered idiopathic in
nature. Both inflammation and ischemia are associ-
ated with focal forms of atrophy.
The relation of prostatic atrophy to neopla-
sia is exciting and controversial. This topic was thor-
oughly commented in our study and discussed in the
editorial comments by Dr.H.Samaratunga, Dr.
Rodolfo Montironi, and Dr. Liang Cheng (6).Figure 1 – Hyperplastic atrophy (or postatrophic hyperplasia).
Figure 2 – Partial atrophy.
Figure 3 – Partial atrophy (immunohistochemistry: 34âE12).
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In diagnostic practice it is not rare to find
patients with serum prostate- specific antigen (PSA)
elevation and several biopsies showing no atypical,
preneoplastic or neoplastic lesions, except prostatic
atrophy. Regardless of the cause, we hypothesized
that damaged epithelial cells in atrophic acini could
be a source of the elevation of PSA. Our study was
based on 131 needle prostatic biopsies correspond-
ing to 107 patients. The only diagnosis in all biopsies
was focal prostatic atrophy without the presence of
cancer, high-grade prostatic intraepithelial neoplasia,
or areas suspicious for cancer. A positive and signifi-
cant association was found between the extent of at-
rophy and the total or free serum PSA elevation (9).
All patients showing 35mm or higher linear extent of
atrophy in the biopsy cores, had serum PSA above
4ng/mL. The findings suggest that damaged epithe-
lial cells in atrophic acini, regardless of cause, could
be a source of serum PSA elevation.
Prostate-specific antigen is a single chain gly-
coprotein with proteolytic enzyme activity mainly di-
rected against the major gel-forming protein of the
ejaculate (semenogelin). PSA induces liquefaction of
semen with release of progressively motile sperma-
tozoa (10). There are several efficient physiologic
barriers to prevent the escape of any significant
amounts of PSA from the prostatic ductal system:
basement membrane of the acini, basal cells lining
the acini, prostatic stroma, basement membrane of
capillary endothelial cells, and endothelial cells. These
barriers normally prevent PSA from entering the gen-
eral circulation at concentrations of more than 3ng/
mL (10).
Focal prostatic atrophy represents a form of
adaptive response to injury most commonly to inflam-
mation and/or local ischemia. It is intriguing that atro-
phic acini may produce an excess of serum PSA. In-
flammation and/or ischemia are injurious stimuli re-
sulting in diminished oxidative phosphorilation, mem-
brane damage, influx of intracellular calcium, and
accumulation of oxygen-derived free radicals (oxi-
dative stress) (11). We speculate that these injurious
stimuli may interfere in the physiologic barrier that
prevent the escape of any significant amounts of PSA
to the general circulation.
Atrophy is a frequent, exciting, intriguing le-
sion and a relevant subject for further research. Pa-
thologists should include the presence and extent of
the lesion in the pathology report.
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